Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 11;25(1):556.
doi: 10.1186/s12889-025-21752-1.

Changes in drinking levels and metabolic dysfunction-associated steatotic liver disease: a longitudinal study from the China multi-ethnic cohort study

Ning Zhang #  1 , Jingzhong Li #  2 , Xiaofen Xie  1 , Yifan Hu  1 , Hongxiang Chen  1 , Yuan Zhang  1 , Yujie Liu  1 , Xingren Zhu  1 , Hao Xu  3 , Zhenghong Wang  4 , Kangzhuo Baima  5 , Xuehui Zhang  6 , Zixiu Qin  7 , Zhimiao Yu  8 , Xiong Xiao  9 , Xing Zhao  1
Affiliations

Changes in drinking levels and metabolic dysfunction-associated steatotic liver disease: a longitudinal study from the China multi-ethnic cohort study

Ning Zhang et al. BMC Public Health. .

Abstract

Background: Little is known about the associations of changes in drinking levels with the newly defined metabolic dysfunction-associated steatotic liver disease (MASLD). We therefore sought to estimate the associations between changes in drinking levels and MASLD in less developed regions of China.

Methods: This longitudinal study included 8727 participants from the China Multi-Ethnic Cohort (CMEC) in less developed regions, all participating in baseline and a follow-up survey. MASLD was defined as hepatic steatosis, along with the presence of at least one of five cardiometabolic risks, in addition to limiting excessive alcohol consumption. We applied the parametric g-formula to evaluate the association between changes in drinking levels and MASLD. We further estimated the association between changes in drinking levels and fibrosis scores (AST-to-platelet ratio and fibrosis-4 index) in patients with MASLD.

Results: Compared with sustained non-drinking, sustained modest drinking was associated with a higher risk of MASLD (Mean Ratio (MR): 1.127 [95% CI: 1.040-1.242]). Compared to sustained non-drinking, the MR for those transitioning from non-drinking to modest drinking was 1.065 [95% CI: 0.983-1.169], while the MR for those changing from modest drinking to non-drinking was 1.059 [95% CI: 0.965, 1.173]. Non-invasive fibrosis scores tended to increase with modest drinking compared to sustained non-drinking.

Conclusion: In the less developed regions of China, sustained moderate drinking was associated with the risk of MASLD compared with sustained non-drinking. Increased drinking showed a trend towards a higher risk of MASLD. This study can inform drinking policies related to MASLD and liver fibrosis in less developed regions.

Keywords: Changes in drinking levels; MASLD; Modest alcohol consumption; NAFLD.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Ethical approvals were obtained by the Sichuan University Medical Ethical Review Board for the CMEC study. The ethical approval was done in accordance with the Declaration of Helsinki. Informed consent to participate was obtained from all of the participants in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Informed consent: Informed consent was obtained from all individual participants included in the study.

Figures

Fig. 1
Fig. 1
The level of alcohol consumption and their changes among the participants in the CMEC
Fig. 2
Fig. 2
Associations between changes in drinking levels and MASLD. The CMEC: the China Multi-Ethnic Cohort; MD: mean difference; MR: mean ratio
Fig. 3
Fig. 3
Associations between changes in drinking levels and noninvasive liver fibrosis scores. The CMEC: the China Multi-Ethnic Cohort; MD: mean difference; MR: mean ratio; FIB-4: fibrosis-4 index; APRI: AST-to-platelet ratio. Among MASLD patients in the follow-up survey (n = 2157), 1787 and 1788 were included in the analyses of FIB-4 and APRI, respectively, after we excluded missing data for calculating hepatic fibrosis scores
See this image and copyright information in PMC

References

    1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol Jul. 2020;73(1):202–9. 10.1016/j.jhep.2020.03.039. - PubMed
    1. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet Jun. 2021;5(10290):2212–24. 10.1016/s0140-6736(20)32511-3. - PubMed
    1. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol Mar. 2019;70(3):531–44. 10.1016/j.jhep.2018.10.033. - PubMed
    1. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatol Mar. 2021;73(3):1194–8. 10.1002/hep.31420. - PubMed
    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol Jun. 2023;20. 10.1016/j.jhep.2023.06.003. - PubMed

LinkOut - more resources